REDWOOD CITY, Calif.,
March 22, 2021 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for use in healthcare
institutions, today announced that management will present an
overview of AcelRx Pharmaceuticals, followed by a fireside chat
with Dr. Pamela Palmer. The
presentation will take place on March 24,
2021 at 9:25 AM EST /
6:25 AM PST, and the fireside chat
will begin at 11:35 AM EST /
8:35 AM PST.
Individuals interested in attending the live events can register
here https://www.benzinga.com/events/small-cap/biotech/. A replay
of the Company's presentation and fireside chat will be available
online in the investor relations section of the Company's website
for 90 days following the events.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA®
(sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in
Europe, indicated for the
management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and one product candidate, Zalviso®
(sufentanil sublingual tablet system, SST system, 15 mcg), an
investigational product in the U.S., is being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings. DZUVEO and Zalviso are both approved products in
Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-announces-presentation-and-fireside-chat-at-the-benzinga-biotech-small-cap-conference-301253108.html
SOURCE AcelRx Pharmaceuticals, Inc.